Clenbuterol Analysis

The Clenbuterol Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clenbuterol in oral dosage forms and raw active pharmaceutical ingredient (API) powders.

The analysis is suitable for pills, tablets, and capsules, with results reported in micrograms per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).

About Clenbuterol

Clenbuterol is a synthetic beta-2 adrenergic agonist with bronchodilator activity. It stimulates beta-2 adrenergic receptors and can affect smooth muscle tone, cardiovascular function, and metabolic processes.

Clenbuterol has been used therapeutically in some countries for respiratory conditions, but it is not approved for human use in many jurisdictions. It is also known for non-medical use related to its stimulant and metabolic effects.

Key Features

• Targeted identification and quantification of clenbuterol
• Suitable for pills, tablets, capsules, and raw API powders
• Analysis by HPLC
• Results for oral products reported in mcg per tablet or capsule
• Results for raw API powders reported as percentage content
• Optional purity reporting in % (m/m) for raw API powders
• Minimum sample amount of three tablets or capsules
• Minimum sample amount of 200 mg for raw API powders
• Average turnaround time of 7 business days

Analysis Parameters

• Target compound: Clenbuterol
• Other name: Clen
• Testing method: HPLC
• Minimum amount of target compound for evaluation in oral products: 15 mcg per pill, tablet, or capsule
• Minimum content of target compound for evaluation in raw API powders: 5%
• Result format for oral products: mcg per tablet or capsule
• Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]
• Minimum sample amount for oral products: Three tablets or capsules
• Minimum sample amount for raw API powders: 200 mg
• Average turnaround time: 7 business days

Important Notice

• This analysis is specifically intended for clenbuterol. It does not automatically screen the sample for other beta-2 agonists, related compounds, contaminants, or undeclared substances.
• For oral products, the minimum amount of clenbuterol required for evaluation is 15 mcg per pill, tablet, or capsule. For raw API powders, the minimum content is 5%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.
• Purity reporting in % (m/m) is available only for raw API powders.

Optional Additional Analyses

The following optional laboratory services are available:

• Complete Raw Analytical Data
• Fentanyl Screening
• Alternative Result Format: Purity in % (m/m)
• Batch Variance Testing
• GC–MS Contamination Screening
• Heavy Metals Analysis (As, Cd, Pb, Hg)
• Additional Laboratory Report